Onconova Therapeutics (NASDAQ: ONTX) Decreased to Hold at Zacks Investment Research

Onconova (NASDAQ: ONTX) was downgraded by Zacks.com  from a “acquire” score to a “hold” rating in a research note released to investors on Thursday, Zacks.com reports.

According to Zacks, “Onconova Therapeutics, Inc. operates as a clinical-stage biopharmaceutical business. It concentrates on discovering as well as establishing small particle medicine candidates to deal with cancer cells. The Business‘s products under various phases of development consist of Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 as well as Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. “

A number of other equities research experts additionally just recently talked about the firm. Noble Financial editioned a “buy” ranking as well as provided a $11.00 price objective on shares of Onconova Therapeutics in a record on Thursday, September 23rd. Guggenheim dropped their price target on Onconova Therapeutics from $29.00 to $12.00 and set a “buy” rating on the stock in a research note on Tuesday, September 28th.

NASDAQ: ONTX opened at $2.25 on Thursday. Onconova Therapeutics has a twelve month low of $2.22 as well as a twelve month high of $28.95. Business has a 50 day moving average rate of $2.90 and a two-hundred day moving average rate of $4.16. The firm has a market cap of $46.76 million, a P/E ratio of -1.82 and also a beta of 1.67.

Onconova Therapeutics (NASDAQ: ONTX) last launched its quarterly profits results on Thursday, November 11th. The biopharmaceutical company reported ($ 0.22) revenues per share for the quarter, topping analysts’ consensus quotes of ($ 0.33) by $0.11. Onconova Therapeutics had a negative return on equity of 59.78% and also an unfavorable net margin of 8,294.27%. The firm had income of $0.06 million during the quarter, contrasted to the agreement quote of $0.06 million. During the exact same quarter in the previous year, the company uploaded ($ 0.45) EPS. As a group, research analysts anticipate that Onconova Therapeutics will certainly publish -1.18 EPS for the current year.

A variety of hedge funds have just recently bought and sold shares of ONTX. GSA Resources Partners LLP acquired a new setting in Onconova Therapeutics throughout the 3rd quarter worth $922,000. Hudson Bay Resources Monitoring LP purchased a new setting in shares of Onconova Therapeutics in the 3rd quarter worth $635,000. Pura Vida Investments LLC acquired a new setting in shares of Onconova Therapeutics in the third quarter worth $575,000. CVI Holdings LLC bought a brand-new setting in shares of Onconova Therapeutics in the third quarter worth $493,000. Ultimately, Dimensional Fund Advisors LP got a brand-new setting in shares of Onconova Therapeutics in the second quarter worth $509,000. Hedge funds as well as other institutional financiers possess 13.36% of the firm’s stock.

Concerning Onconova Therapeutics

Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical firm, which takes part in the identification and development of oncology therapeutics. It focuses on discovering and also establishing tiny molecule drug prospects to treat cancer cells. The firm was founded by Ramesh Kumar and also E. Premkumar Reddy on December 22, 1998 as well as is headquartered in Newtown, PA

. Get a totally free copy of the Zacks research record on Onconova Therapeutics (ONTX).

For additional information regarding research offerings from Zacks Investment Research, see Zacks.com.

This instant news alert was produced by narrative science technology and financial data from Market in order to give readers with the fastest as well as most accurate coverage. This tale was evaluated by Market’s content team prior to magazine. 



Prior to you consider Onconova Therapeutics, you’ll wish to hear this.

Market tracks Wall Street’s premier and ideal executing research analysts as well as the stocks they advise to their clients daily. Market has identified the five stocks that cover analysts are silently murmuring to their clients to purchase currently prior to the broader market catches on … as well as Onconova Therapeutics wasn’t on the checklist.

While Onconova Therapeutics presently has a “Buy” score among experts, top-rated analysts think these 5 stocks are much better buys.